Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Lawrence J Green MD Llc

Neither a doctor nor a teaching hospital

Research payments

$1,527,840

456 payments

Through program year 2025, Lawrence J Green MD Llc is reported as receiving $1,527,840 in research payments, across 456 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $164,537 32
2024 Research $206,332 224
2023 Research $363,918 147
2022 Research $91,786 23
2021 Research $120,759 5
2020 Research $121,199 7
2019 Research $459,309 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $677,839 17 payments
  2. Janssen Research & Development, LLC $321,424 46 payments
  3. Pfizer Inc. $145,488 37 payments
  4. Dermavant Sciences, Inc. $96,770 318 payments
  5. Endo Pharmaceuticals Inc. $88,478 8 payments
  6. Bausch Health US, LLC $70,784 9 payments
  7. Aclaris Therapeutics, Inc. $55,975 12 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $28,996 2 payments
  9. E.R. Squibb & Sons, L.L.C. $25,978 4 payments
  10. Amgen Inc. $11,234 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $205,654 6 payments
  2. Cnto1959pso3018 $205,359 20 payments
  3. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $201,032 3 payments
  4. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $200,015 4 payments
  5. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo $93,945 23 payments
  6. A Phase 2B, Open-Label Long-Term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite) $88,478 8 payments
  7. A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of Idp-126 Gel to Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris $70,784 9 payments
  8. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $55,975 12 payments
  9. A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis $53,810 7 payments
  10. An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $52,071 51 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record